Supported by one trial
One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
Masitinib: slow disability worsening in primary progressive MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
primary progressive MS · Microglia / innate immunity in the CNS
One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Trials
- 4
- Running now
- 1
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 1601
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 3
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2024 · Placebo-controlled · MSFT-2024-516672-16-00
Phase 3 · 2022 · Placebo-controlled · MSFT-NCT05441488
- Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosisdecides the statusMet main goal
Phase 3 · 2011 · Placebo-controlled · MSFT-NCT01433497
Masitinib (4.5 mg/kg/d) (n = 199) showed significant benefit over placebo (n = 101) according to the primary end point, 0.001 vs 0.098, respectively, with a between-group difference of -0.097 (97% CI -0.192 to -0.002); p = 0.0256.
Read by software from the paper's abstract
Other linked trials: 3
These linked trials do not set the status.
- Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisMissed main goal
Phase 2 · 2005 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-11-02Status changed from Confirmed to Supported by one trial
- 2026-10-28First listed as Confirmed
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error